Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression. a review of the evidence

Urologic Oncology
S R. DowningP J. Russell

Abstract

Mutations in the p53 tumour suppressor gene are generally believed to be a late event in the progression of prostate cancer, and are associated with androgen independence, metastasis, and a worse prognosis. In this review, we examine the current literature available on p53 mutations and focus on stages A (T1) and B (T2) of prostate cancer. We report here that p53 mutations can be found in approximately one third of prostate cancers that are clinically localized to the prostate. In addition, high levels of p53 mutation are found in normal prostate tissue of prostate cancer patients, prostatic intraepithelial neoplasia, and benign prostatic hyperplasia. The limitations of techniques used to determine p53 mutations are discussed, as well as other modes of p53 loss in early stage prostate cancer.

References

Sep 30, 1992·International Journal of Cancer. Journal International Du Cancer·A RotolaE Cassai
Jun 1, 1992·British Journal of Urology·S J ThompsonD E Neal
May 14, 1992·The New England Journal of Medicine·A J Levine
Jun 6, 1991·Nature·A J LevineC A Finlay
Nov 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·D EliyahuM Oren
Jun 15, 1994·Journal of the National Cancer Institute·S G ChiP H Gumerlock
Apr 21, 1995·International Journal of Cancer. Journal International Du Cancer·C Moyret-LalleC Theillet
Jun 1, 1995·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·M Tommasino, L Crawford
Oct 20, 1993·Journal of the National Cancer Institute·N M NavoneC J Conti
Nov 17, 1993·Journal of the National Cancer Institute·F J MeyersP H Gumerlock
Apr 11, 1995·Proceedings of the National Academy of Sciences of the United States of America·N M GreenbergJ M Rosen
Dec 1, 1994·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·K FanL M Fink
Nov 8, 1994·Proceedings of the National Academy of Sciences of the United States of America·I G MaroulakouJ E Green
Jan 1, 1994·Journal of Cancer Research and Clinical Oncology·T WiethegeK M Müller
Mar 1, 1994·International Journal of Cancer. Journal International Du Cancer·W N DinjensJ Trapman
Jan 1, 1993·The Prostate·P J Van VeldhuizenR L Stephens
Oct 9, 1996·Biochimica Et Biophysica Acta·H zur Hausen
Dec 1, 1996·Diagnostic Molecular Pathology : the American Journal of Surgical Pathology, Part B·X B ShiP H Gumerlock
Jan 15, 1997·Journal of the National Cancer Institute·D J GrignonJ D Cox
Feb 1, 1997·British Journal of Urology·R L ByrneF C Hamdy
Jan 1, 1997·Current Opinion in Oncology·J T DongJ T Isaacs
May 15, 1997·Nature·Y HauptM Oren
May 15, 1997·Nature·M H KubbutatK H Vousden
Aug 1, 1997·The Journal of Urology·C E SalemR J Cote
Aug 28, 1997·Oncogene·J PietteV Maréchal
Jul 22, 1998·Nucleic Acids Research·J MomandJ Niland
Nov 21, 1998·Oncogene·S Y FuchsZ Ronai
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·E M GarabedianJ I Gordon

❮ Previous
Next ❯

Citations

Mar 19, 1996·Cancer Letters·K YaneY Hiasa
Feb 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R ShipmanC Ludwig
Jul 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M G DaidoneR Silvestrini
Sep 1, 1994·European Journal of Cancer. Part B, Oral Oncology·J E BurnsE K Parkinson
Sep 11, 2013·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Ruriko YamadaTakao Fukaya
Sep 2, 1998·Cancer Genetics and Cytogenetics·R A DiCioccioM S Piver
Sep 2, 1998·Cancer Genetics and Cytogenetics·F PompettiG Palka
Jul 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M MurphyS E Russell
Jul 1, 1997·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·I HeideC F Rochlitz
Jan 23, 2003·Cancer Biotherapy & Radiopharmaceuticals·Xu-Bao ShiRalph W deVere White
Mar 23, 2004·Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia·Jana Knillová, Zdenek Kolár
Mar 18, 2008·Free Radical Biology & Medicine·Sanjeev Shukla, Sanjay Gupta
Jan 5, 2002·Polish Journal of Pathology : Official Journal of the Polish Society of Pathologists·W M Murphy
Oct 1, 2003·The Prostate·Adrie van BokhovenM Scott Lucia
Jun 3, 2006·The Prostate·Marcio C Bajgelman, Bryan E Strauss
Jan 31, 2009·Journal of Cellular Biochemistry·Hezhe LvYu-Sheng Cong
Jul 17, 2019·Journal of Experimental & Clinical Cancer Research : CR·Monika AggarwalFung-Lung Chung
May 1, 2013·Personalized Medicine·Won Kim, Phillip G Febbo
Jan 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ying DongJinming Gao
May 9, 2012·Disease Models & Mechanisms·Ruth L VinallAlexander D Borowsky
May 15, 2007·Human Pathology·William M Murphy

❮ Previous
Next ❯

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.